Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 9.6% – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE) fell 9.6% on Wednesday . The company traded as low as $26.96 and last traded at $29.32. 111,833 shares changed hands during trading, a decline of 62% from the average session volume of 298,220 shares. The stock had previously closed at $32.42.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MAZE. Wedbush began coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an “outperform” rating and a $17.00 target price for the company. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. BTIG Research raised their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Finally, Guggenheim raised their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $33.83.

Maze Therapeutics Stock Down 7.1%

The company’s fifty day moving average is $24.94 and its 200-day moving average is $16.89. The company has a market cap of $1.32 billion and a PE ratio of -1.49.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. New York State Common Retirement Fund lifted its stake in shares of Maze Therapeutics by 191.3% during the 3rd quarter. New York State Common Retirement Fund now owns 6,700 shares of the company’s stock valued at $174,000 after buying an additional 4,400 shares in the last quarter. Washington University bought a new stake in Maze Therapeutics in the 3rd quarter valued at $5,463,000. SG Americas Securities LLC bought a new stake in Maze Therapeutics in the 3rd quarter valued at $130,000. Tower Research Capital LLC TRC increased its holdings in Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after acquiring an additional 3,774 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. increased its holdings in Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares during the last quarter.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.